As of Apr 24
| -0.51 / -0.20%|
The 17 analysts offering 12-month price forecasts for Pharmacyclics Inc have a median target of 261.00, with a high estimate of 261.25 and a low estimate of 184.00. The median estimate represents a +1.72% increase from the last price of 256.59.
The current consensus among 19 polled investment analysts is to Hold stock in Pharmacyclics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.